Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN105 in healthy Chinese volunteers
NCT07801313Phase 1Completed
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWN105 in obesity, type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Incidence of adverse events. Started Dec 2024; status: completed.
02
Drugs
MWN105
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07801313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801313.